Iambic Therapeutics priced a $150 million IPO, starting trading Thursday after selling 9.38 million shares at $16 each. The cancer-focused company positions its AI-driven platform as a way to accelerate early discovery and expand its pipeline faster than traditional approaches. The offering highlights investor appetite for AI-led drug development models, but also underscores the near-term pressure on new public biotechs to translate platform claims into credible clinical progress and partnering momentum.